<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35397078</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7217</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>193</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Breast cancer research and treatment</Title>
          <ISOAbbreviation>Breast Cancer Res Treat</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.</ArticleTitle>
        <Pagination>
          <StartPage>437</StartPage>
          <EndPage>444</EndPage>
          <MedlinePgn>437-444</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-022-06585-5</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Circulating tumor cells (CTCs) are prognostic in patients with breast cancer. Several technical platforms exist for their enumeration and characterization. Comparative studies between these platforms are scarce. The RareCyte CTC detection is theoretically more sensitive than the established CellSearch platform, which identifies only CTCs that express EpCAM and cytokeratin. This study prospectively compares CTC enumeration in patients with breast cancer in a paired analysis using these two platforms. It investigates survival outcomes in groups defined by a CTC count threshold.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">CTC enumeration was performed on 100 samples obtained from 86 patients with progressive metastatic breast cancer (MBC) in two independent laboratories each blinded to the clinical data and the results from the other platform.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred paired samples were collected and CTC counts were determined using the CellSearch and RareCyte CTC platforms. In total, 65% and 75% of samples had at least one detectable CTC in 7.5 mL blood with the CellSearch and the RareCyte systems, respectively. CTC counts with the CellSearch system ranged from 0 to 2289 with a median of 3 CTCs, the RareCyte CTC counts ranged from 0 to 1676 with a median of 3 CTCs. The number of samples with 5 or more CTCs in 7.5 mL of blood (the poor prognosis cut-off validated with the CellSearch system) blood was 45% with the CellSearch test and 48% with the RareCyte test. CTC counts quantified with the CellSearch and the RareCyte systems were strongly correlated (Spearman's r = 0.8235 (0.7450-0.8795) p &lt; 0.001). 86 patients were included for Kaplan-Meier survival analysis. An increased mortality risk in patients with CellSearch of 5 CTCs or more per 7.5 mL blood, with a log-rank hazard ratio of 5.164 (2.579-10.34) (p &lt; 0.001) was confirmed. The survival analysis with RareCyte CTC counts with the identical cut-off showed a significantly impaired survival with a hazard ratio of 4.213 (2.153-8.244) (p &lt; 0.001).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data demonstrate the analytical and prognostic equivalence of CellSearch and RareCyte CTC enumeration platforms in patients with MBC using the CellSearch cut-off. This is the first demonstration of prognostic significance using the RareCyte platform.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dirix</LastName>
            <ForeName>Luc</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-7792-9964</Identifier>
            <AffiliationInfo>
              <Affiliation>GZA Sint Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium. luc.dirix@gza.be.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buys</LastName>
            <ForeName>Andy</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>GZA Sint Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oeyen</LastName>
            <ForeName>Steffy</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>GZA Sint Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peeters</LastName>
            <ForeName>Dieter</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>CellCarta, Sint-Bavostraat 78-80, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liègeois</LastName>
            <ForeName>Vincent</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>GZA Sint Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prové</LastName>
            <ForeName>Annemie</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>GZA Sint Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rondas</LastName>
            <ForeName>Dieter</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>CellCarta, Sint-Bavostraat 78-80, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vervoort</LastName>
            <ForeName>Liesbet</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>CellCarta, Sint-Bavostraat 78-80, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mariën</LastName>
            <ForeName>Véronique</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>CellCarta, Sint-Bavostraat 78-80, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laere</LastName>
            <ForeName>Steven Van</ForeName>
            <Initials>SV</Initials>
            <AffiliationInfo>
              <Affiliation>GZA Sint Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vermeulen</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>GZA Sint Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Breast Cancer Res Treat</MedlineTA>
        <NlmUniqueID>8111104</NlmUniqueID>
        <ISSNLinking>0167-6806</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="Y">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CellSearch</Keyword>
        <Keyword MajorTopicYN="N">Circulating tumor cells,</Keyword>
        <Keyword MajorTopicYN="N">Metastatic breast cancer</Keyword>
        <Keyword MajorTopicYN="N">RareCyte</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35397078</ArticleId>
        <ArticleId IdType="pmc">PMC9090706</ArticleId>
        <ArticleId IdType="doi">10.1007/s10549-022-06585-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s10549-022-06585-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alix-Panabières C, Pantel K. Liquid Biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858–873. doi: 10.1158/2159-8290.CD-20-1311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-20-1311</ArticleId>
            <ArticleId IdType="pubmed">33811121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Eng J Med. 2004;351:781–791. doi: 10.1056/NEJMoa040766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa040766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15:406–414. doi: 10.1016/S1470-2045(14)70069-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70069-5</ArticleId>
            <ArticleId IdType="pubmed">24636208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, et al.  Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res. 2016;22:2583–2593. doi: 10.1158/1078-0432.CCR-15-1603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1603</ArticleId>
            <ArticleId IdType="pubmed">26733614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, et al.  Circulating tumour cell detection: a direct comparison between the cell search system, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Brit J Cancer. 2010;102:276–284. doi: 10.1038/sj.bjc.6605472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6605472</ArticleId>
            <ArticleId IdType="pmc">PMC2816650</ArticleId>
            <ArticleId IdType="pubmed">19953098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al.  Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904. doi: 10.1158/1078-0432.CCR-04-0378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-0378</ArticleId>
            <ArticleId IdType="pubmed">15501967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaldjian EP, Ramirez AB, Sun Y, Campton DE, Werbin JL, Varshavskaya P, et al.  The RareCyte(R) platform for next-generation analysis of circulating tumor cells. Cytometry A. 2018;93:1220–1225. doi: 10.1002/cyto.a.23619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cyto.a.23619</ArticleId>
            <ArticleId IdType="pmc">PMC6586054</ArticleId>
            <ArticleId IdType="pubmed">30277660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campton DE, Ramirez AB, Nordberg JJ, Drovetto N, Clein AC, Varshavskaya P, Friemel BH, Quarre S, Breman A, Dorshner M, Blau S, Blau CA, Sabath DE, Stilwell JL, Kaldjian EP. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015;15:360. doi: 10.1186/s12885-015-1383-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-015-1383-x</ArticleId>
            <ArticleId IdType="pmc">PMC4430903</ArticleId>
            <ArticleId IdType="pubmed">25944336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blau CA, Ramirez AB, Blau S, Pritchard CC, Dorschner MO, et al.  A distributed network for intensive longitudinal monitoring in metastatic triple-negative breast cancer. J Natl Compr Canc Netw. 2016;14:8–17. doi: 10.6004/jnccn.2016.0003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2016.0003</ArticleId>
            <ArticleId IdType="pmc">PMC4970582</ArticleId>
            <ArticleId IdType="pubmed">26733551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stilwell JL, Drovetto N, Ramirez AB, Campton D, Nordberg J, Varshavskaya P, et al. Abstract 1601: Clinical performance of the AccuCyte® - CyteFinder® System, a dual-technology platform for comprehensive collection and high-resolution imaging of circulating tumor cells. Cancer Research. 2015; 75 (15 Supplement):1601-.</Citation>
        </Reference>
        <Reference>
          <Citation>Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al.  Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101:61–66. doi: 10.1093/jnci/djn419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djn419</ArticleId>
            <ArticleId IdType="pmc">PMC2639293</ArticleId>
            <ArticleId IdType="pubmed">19116383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Laere SJ, Elst H, Peeters D, Benoy I, Vermeulen PB, Dirix LY. Re: anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101:895–896. doi: 10.1093/jnci/djp116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djp116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DF, et al.  Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res. 2015;21:2771–2779. doi: 10.1158/1078-0432.CCR-14-2781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2781</ArticleId>
            <ArticleId IdType="pmc">PMC5521206</ArticleId>
            <ArticleId IdType="pubmed">25779948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, et al.  Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Brit J Cancer. 2014;110:375–383. doi: 10.1038/bjc.2013.743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.743</ArticleId>
            <ArticleId IdType="pmc">PMC3899770</ArticleId>
            <ArticleId IdType="pubmed">24366294</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
